Immunic, Inc. Common Stock

Immunic, Inc. (IMUX) is a clinical-stage biopharmaceutical company focused on developing oral therapies for autoimmune and inflammatory diseases. The company's pipeline includes immune-modulating treatments aimed at conditions such as multiple sclerosis, ulcerative colitis, and psoriasis. Immunic's approach leverages innovative small molecule compounds designed to target specific pathways involved in immune system regulation.